4563 Stock Overview
A biopharmaceutical company, engages in the research and development of gene-based medical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥66.00 |
| 52 Week High | JP¥98.00 |
| 52 Week Low | JP¥43.00 |
| Beta | 0.65 |
| 11 Month Change | -7.04% |
| 3 Month Change | 50.00% |
| 1 Year Change | -31.96% |
| 33 Year Change | -90.56% |
| 5 Year Change | -90.15% |
| Change since IPO | -96.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4563 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -9.6% | 3.8% | 3.7% |
| 1Y | -32.0% | 17.1% | 14.4% |
Return vs Industry: 4563 underperformed the JP Biotechs industry which returned 17.1% over the past year.
Return vs Market: 4563 underperformed the JP Market which returned 14.4% over the past year.
Price Volatility
| 4563 volatility | |
|---|---|
| 4563 Average Weekly Movement | 23.5% |
| Biotechs Industry Average Movement | 13.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in JP Market | 10.4% |
| 10% least volatile stocks in JP Market | 3.5% |
Stable Share Price: 4563's share price has been volatile over the past 3 months.
Volatility Over Time: 4563's weekly volatility has increased from 13% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
| 4563 fundamental statistics | |
|---|---|
| Market cap | JP¥15.21b |
| Earnings (TTM) | -JP¥6.11b |
| Revenue (TTM) | JP¥448.00m |
36.1x
P/S Ratio-2.7x
P/E RatioIs 4563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4563 income statement (TTM) | |
|---|---|
| Revenue | JP¥448.00m |
| Cost of Revenue | JP¥276.00m |
| Gross Profit | JP¥172.00m |
| Other Expenses | JP¥6.28b |
| Earnings | -JP¥6.11b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -24.89 |
| Gross Margin | 38.39% |
| Net Profit Margin | -1,363.17% |
| Debt/Equity Ratio | 0% |
How did 4563 perform over the long term?
See historical performance and comparison